RDY News Alert Dr. Reddy's Laboratories Ltd (RDY) 49.58 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dr. Reddy's Laboratories Ltd (RDY) 49.58 $RDY

Dr. Reddy's Laboratories acquires Habitrol Brand from Novartis
M2 - Fri Dec 19, 7:09AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Thursday the completion of the acquisition of title and rights of Habitrol brand from Novartis Consumer Health under an asset purchase agreement.
RDY: 49.58 (-0.10), NVS: 93.91 (+0.66)

Dr. Reddy's Laboratories Closes the Acquisition of Habitrol(R) Brand from Novartis
Business Wire - Fri Dec 19, 1:18AM CST
Dr. Reddy's Laboratories has announced that it has closed the acquisition of Habitrol(R) brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc. following issuance of the proposed consent order from the U.S. Federal Trade Commission (FTC) on November 26, 2014. The company had earlier entered into an asset purchase agreement with Novartis Consumer Health Inc. to acquire the title and rights of Habitrol(R) brand and to market the product in the U.S. market.
RDY: 49.58 (-0.10), NVS: 93.91 (+0.66)

Dr. Reddy's Laboratories (RDY) in Focus: Stock Falls 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:06AM CST
Dr. Reddy's Laboratories stock fell over 7% last trading session, continuing its recent downtrend
AKRX: 36.47 (+0.43), RDY: 49.58 (-0.10)

Stock Futures Point Lower; Russia, India Stocks Pressured
at Investor's Business Daily - Tue Dec 16, 8:20AM CST
Stock futures were moderately lower ahead of Tuesday's open, despite volatile overseas stock and currency trading. Dow futures were 29.8 points below fair market value and off their early lows. Nasdaq 100 futures were under some serious pressure,...
TLM: 7.84 (unch), RUSS: 24.00 (-2.60), RDY: 49.58 (-0.10), NUGT: 10.13 (+0.76), IBN: 11.65 (+0.08), JNUG: 20.87 (+2.01), HDB: 50.86 (-0.06), RSX: 15.95 (+0.51), YNDX: 17.66 (-0.32)

Dr. Reddy's launches generic version of Valcyte in U.S.
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 7:19AM CST

RDY: 49.58 (-0.10)

Dr. Reddy's unveils Valganciclovir Tablets, USP in the US
M2 - Tue Dec 16, 6:15AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Tuesday the availability of Valganciclovir Tablets USP 450 mg in the US market on 15 December 2014.
RDY: 49.58 (-0.10)

Dr. Reddy's Announces the Launch of Valganciclovir Tablets, USP
Business Wire - Tue Dec 16, 1:57AM CST
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE(R) (Valganciclovir) tablets in the US market on December 15, 2014, approved by the United States Food & Drug Administration (USFDA).
RDY: 49.58 (-0.10)

Dr Reddys Laboratories Up 16.2% Since SmarTrend Uptrend Call (RDY)
Comtex SmarTrend(R) - Mon Dec 01, 11:21AM CST
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on October 23rd, 2014 at $50.46. In approximately 1 month, Dr Reddys Laboratories has returned 16.22% as of today's recent price of $58.64.
RDY: 49.58 (-0.10)

FTC gives thumbs up to Glaxo/Novartis transaction
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 2:48PM CST

RDY: 49.58 (-0.10), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)

Dr. Reddy's unveils Docetaxel Injection USP in the US market
M2 - Mon Nov 24, 7:16AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) disclosed on Monday the availability of Docetaxel Injection USP 20 mg/ml and 80 mg/4 ml in a single dose and one vial formulation in the US market.
RDY: 49.58 (-0.10)

Dr. Reddy's Announces the Launch of Docetaxel Injection USP
Business Wire - Mon Nov 24, 1:29AM CST
Dr. Reddy's Laboratories (NYSE: RDY) announced today that is has launched Docetaxel Injection USP 20 mg/mL and 80 mg/4 mL a therapeutic equivalent generic version of TAXOTERE(R) (docetaxel Injection) in the US market on November 21, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA).
RDY: 49.58 (-0.10)

Dr. Reddy's unveils OTC Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg ERTablets in the US
M2 - Fri Nov 21, 5:30AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) disclosed on Thursday the introduction of its US FDA approved over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg in a 20 count blister in the US market.
RDY: 49.58 (-0.10)

Dr. Reddy's Announces the Launch of Over-the-Counter Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets
Business Wire - Thu Nov 20, 8:15AM CST
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg, a bioequivalent generic version of Allegra-D(R) 12 Hour Allergy & Congestion, in the U.S. market on November 18, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA).
RDY: 49.58 (-0.10)

Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 3:30PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) and partner Takeda Pharmaceutical Company Limited filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (RDY).
JAZZ: 165.33 (+1.83), ARQL: 1.15 (+0.01), SCMP: 13.75 (+0.44), RDY: 49.58 (-0.10)

Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST

ENDP: 72.10 (+0.34), RDY: 49.58 (-0.10)

Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 97.84 (-0.29), ACT: 254.20 (-1.68), MYL: 56.97 (+0.39), RDY: 49.58 (-0.10)

Dr. Reddy's Laboratories (RDY) Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 12:50AM CDT

RDY: 49.58 (-0.10)

Dr. Reddys ups revenues 7% in FQ2
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:43PM CDT

RDY: 49.58 (-0.10)

Dr. Reddy's FQ2 EPS of $0.54
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 5:55AM CDT

RDY: 49.58 (-0.10)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 302

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 72

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Future of Energy: Upgrading America's Aging Power Grid

Updated Category News Views 219

The Energy Conundrum Let’s face it, folks, the electric grid we’re using is like a beat-up old car—driving it won’t get any easier unless we pour in some cash and elbow grease. We all know increasing demand for power is putting the squeeze on the infrastructure, and everybody from policymakers to average homeowners is feeling the pinch. Do a little research (or...

Continue Reading
Cove Capital Investments Boosts Annual Distribution Rates Again

Updated Category News Views 69

Cove Capital Investments Announces Distribution Rate Increase The recent announcement regarding the increase in distribution rates by Cove Capital Investments highlights the success of its unique value-add strategy. This strategy is elaborated in the Private Placement Memorandum when the multifamily offering was made available to accredited investors. Performance of Cove...

Continue Reading
Broadcom Surges in After-Hours Trading on Stellar Earnings

Updated Category News Views 268

Broadcom Inc Reports Strong Earnings Broadcom Inc (NASDAQ: AVGO) experienced a remarkable 12.82% increase in its shares during after-hours trading after unveiling its first-quarter results. This rally followed a 6.33% decline during the regular trading hours, which was part of a larger trend of selloffs in the artificial intelligence (AI) chip market. Significant...

Continue Reading
Recent Downgrades: Analysts Weigh In on Key Stocks

Updated Category News Views 162

Analysts' Outlook on Key Stocks Recent changes from top Wall Street analysts revealed a shift in outlook on several prominent companies. Their evaluations often impact market trends and investor sentiment towards various stocks. Invivyd Inc Downgraded D. Boral Capital's Jason Kolbert downgraded the rating for Invivyd Inc (NASDAQ: IVVD) from Buy to Hold. On the trading...

Continue Reading
Innovative Grip Module Redefines Firearm Handling Experience

Updated Category News Views 299

Revolutionizing Firearm Grip with Innovative Design In the realm of firearm accessories, innovation often leads to transformative user experiences. One such breakthrough comes in the form of the 2911 Grip Module. This specially designed grip module addresses the common issues faced by firearm enthusiasts, offering a solution that enhances both comfort and usability. What...

Continue Reading